Gain Therapeutics (GANX) Presents Preclinical GT-02287 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
October 7, 2024 7:00 AM EDTGT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinsons Disease Models
GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinsons Disease Models
GT-02287 Prevents Tau Accumulation in a Cellular Model
BETHESDA, Md., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of new evidence supporting the disease-modifying activity of GT-02287 in... More
